Literature DB >> 22015216

[Diabetes management issues for patients with chronic kidney disease].

Asmaa Oulahiane1, Sara Anaddam, Hassan Ouleghzal, Nadia Elhaddad, Souad Moussaoui, Noussaima Yaagoubi, Fatima Boufares, Ghizlaine Belmejdoub.   

Abstract

Chronic kidney disease is in continuous increase and can be found in up to 23% of patients with diabetes. Glycemic control is difficult to assess and medication therapy for diabetes may require dose adjustments part of the alteration of drug's pharmacokinetics and the insulin resistance which is predicting cardiovascular events. The recommended hemoglobin A1c goal is also lower than 7.0% without hypoglycemia. In this article, we review the therapeutic management of diabetic patients in chronic renal failure stage which is difficult and the ways to control blood glucose. Multidisciplinary approach, which is including management of comorbid diseases, is necessary to provide the optimal care of these patients.
Copyright © 2011. Published by Elsevier SAS.

Entities:  

Mesh:

Year:  2011        PMID: 22015216     DOI: 10.1016/j.nephro.2011.07.410

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  9 in total

1.  Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

Authors:  Jia Miao; Ping Fu; Shuang Ren; Chao Hu; Ying Wang; Chengfeng Jiao; Ping Li; Yu Zhao; Cui Tang; Yuli Qian; Rong Yang; Yanli Dong; Jing Rong; Yaohui Wang; Xiaowei Jin; Yu Sun; Li Chen
Journal:  Clin Transl Sci       Date:  2021-11-11       Impact factor: 4.689

Review 2.  Metformin associated lactic acidosis (MALA): clinical profiling and management.

Authors:  Alessandra Moioli; Barbara Maresca; Andrea Manzione; Antonello Maria Napoletano; Daniela Coclite; Nicola Pirozzi; Giorgio Punzo; Paolo Menè
Journal:  J Nephrol       Date:  2016-01-22       Impact factor: 3.902

3.  Glucose lowering therapeutic strategies for type 2 diabetic patients with chronic kidney disease in primary care setting in france: a cross-sectional study.

Authors:  N Grandfils; B Detournay; C Attali; D Joly; D Simon; B Vergès; M Toussi; Y Briand; O Delaitre
Journal:  Int J Endocrinol       Date:  2013-04-04       Impact factor: 3.257

4.  Evaluation of the Prevalence of Chronic Kidney Disease and Rates of Oral Antidiabetic Prescribing in Accordance with Guidelines and Manufacturer Recommendations in Type 2 Diabetic Patients within a Long-Term Care Setting.

Authors:  Ning Wu; Xia Yu; Mallik Greene; Gary Oderda
Journal:  Int J Nephrol       Date:  2014-02-25

5.  Prevalence and comorbidities of known diabetes in northeastern Italy.

Authors:  Francesca Valent; Silvia Tillati; Loris Zanier
Journal:  J Diabetes Investig       Date:  2013-02-21       Impact factor: 4.232

6.  Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin.

Authors:  Wanyi Tai; Ran Mo; Jin Di; Vinayak Subramanian; Xiao Gu; John B Buse; Zhen Gu
Journal:  Biomacromolecules       Date:  2014-09-30       Impact factor: 6.988

7.  Optimal LDR to Protect the Kidney From Diabetes: Whole-Body Exposure to 25 mGy X-rays Weekly for 8 Weeks Efficiently Attenuates Renal Damage in Diabetic Mice.

Authors:  Jie Cheng; Fengsheng Li; Guanjun Wang; Weiying Guo; Shan Huang; Brain Wang; Cai Li; Qisheng Jiang; Lu Cai; Jiuwei Cui
Journal:  Dose Response       Date:  2018-09-06       Impact factor: 2.658

8.  Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.

Authors:  Dominique Xavier Brown; Marc Evans
Journal:  J Nutr Metab       Date:  2012-10-18

9.  Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.

Authors:  Nobuya Inagaki; Kazuoki Kondo; Toru Yoshinari; Manabu Ishii; Masaki Sakai; Hideki Kuki; Kenichi Furihata
Journal:  Clin Drug Investig       Date:  2014-10       Impact factor: 2.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.